The safety and efficacy of erlotinib compared with standard chemotherapy in the first-line treatment of Asian and European patients with advanced EGFR mutation-positive NSCLC were assessed in the OPTIMAL and EURTAC trials, respectively [34, 35]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.